Global Multiple Sclerosis Market Research and Forecast 2018-2023

Posted by Orion Market Research on July 19th, 2018

Multiple Sclerosis (MS) is a disease that affects the central nervous system, including the brain and spinal cord. The damage results in disrupting the ability of the nervous system to communicate. In addition, its symptoms can comprise muscle weakness, double vision and blind weakness. People with multiple sclerosis may also develop paralysis, epilepsy and mental problems (depression and mood swings). However, its signs and symptoms may differ depending on the nerve damage as well as affected nerves. In addition, there is a significant rise in incidences of MS has witnessed, which in turn is encouraging the growth of the global multiple sclerosis market. For instance, according to the estimation of the National Multiple Sclerosis Society (NMSS), nearly 1 million people in the U.S. are suffering from MS. It is above double the long-accepted figure of 400,000. Currently, there is no cure available for MS. Although, the treatment can help in faster recovery from attacks as well as change the disease course and manage symptoms.

Presently, the best strategies used in the treatment of MS are disease modified therapies (DMTs). It decreases the severity and frequency of attacks as well as the development of new lesions. The therapy enables to slow down the growth of disability. DMTs are available for relapsing-remitting MS (RRMS), primary progressive MS (PPMS) and secondary progressive MS (SPMS). The latest addition to the DMT includes ocrelizumab (Ocrevus) by Hoffman-La-Roche AG. It is a drug approved by FDA in 2017. This enables for the treatment of relapsing MS. In addition, it is also firstly approved for the treatment of PPMS. It has shown in the research that ocrelizumab is helpful to significantly decrease relapses and slow down the growth of symptoms in PPMS. Like other MS treatments, it is an immunosuppressant drug. Though, most of the MS drug targets T cells, it targets a subset of B cells that play an essential role in the destruction of myelin. As per the phase III clinical trial, the drug enables to considerably reduce relapses rate and inflammatory lesions as well as cut back disability with a significant ratio. As a result, patients taking ocrelizumab had less loss of brain volume and fewer brain lesions as compared to the placebo group.

Related Reports: Healthcare Industry Research

Moreover, there are certain drugs which are in the clinical phase which includes Laquinimod (also referred to as Nerventra) by Active Biotech AB & Teva Pharmaceuticals Ltd. It is an experimental drug in phase II trial for PPMS and phase III trial for relapsing MS. As per the researches, it has represented that Laquinimod contains both neuroprotective and anti-inflammatory actions. As per the phase III ALLEGRO study, it has decreased the annualized relapse rate by 23% as well as the disability progression by 36%. It was also effective on various MRI results comprising a decline in brain atrophy by 33%. This study involves 1,106 individuals with RRMS. Likewise, another drug named Siponimod by Novartis International AG is also in the clinical phase for the assessment of the efficiency in the treatment of people with SPMS. It works by trapping B cells and T cells in the lymph nodes of the body. As a result, it prevents them from entering the spinal cord and brain as well as causing harm to myelin. Under the phase III clinical trial, researchers found the 32% of those individuals taking placebo has undergone a 3 months rise in disability. However, it is comparatively less, such as 26% of those taking Siponimod. It was also found that Siponimod is helpful to reduce MRI-detected brain lesion volume. The FDA approval process seems to be extremely stringent for MS drugs as it is taking a long time. Therefore, it is a major concern for the manufacturers of these drugs and further acting as a key issue for the growth of the global multiple sclerosis market.

Browse full report at: Multiple Sclerosis Market

Furthermore, there are various organizations and companies supporting the researches on MS. For example, In Oct 2017, Merck declared recipients for MS Innovation (GMSI). It offers up to nearly ,684 million grant to support the researches of institutions, including the Department of Neurology & Neurotherapeutics, UT Southwestern Medical Center, Texas US and others. According to Merck, this grant helps in the augmented diagnosis of MS and advanced monitoring of progressions of the disease. This will provide a hope to the healthcare providers and patients with MS to live a normal life. Similarly, Multiple Sclerosis Society of Canada and Multiple Sclerosis Society UK are the certain organizations involved in providing funding to MS researches. These initiatives help in the discovery of new drugs for the treatment of the condition, which is further supporting to accelerate the global multiple sclerosis market.